•
Mar 31, 2021
Krystal Biotech Q1 2021 Earnings Report
Reported financial results for the first quarter ending March 31, 2021 and provided an update on operational progress.
Key Takeaways
Krystal Biotech reported financial results and key operational progress updates for the first quarter ending March 31, 2021. The company completed enrollment in the pivotal GEM-3 trial of B-VEC in dystrophic epidermolysis bullosa (DEB) and had cash, cash equivalents and short-term investments of $403.4 million.
Completed enrollment in pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB).
Topline data from the GEM-3 study is anticipated in 4Q21.
Initiate a Phase 1 study of KB407 in 3Q21.
Cash, cash equivalents and short-term investments totaled $403.4 million on March 31, 2021.